FDA OKs Abilify for secondary use against bipolar disorder

PRINCETON, N.J.—Bristol-Myers Squibb Co. and Japanese partner Otsuka Pharmaceutical Co. said Thursday federal regulators expanded approval for Abilify to aid with the treatment of bipolar disorder.

The companies said the Food and Drug Administration approved their drug as a secondary therapy alongside lithium and valproate for treating bipolar episodes in adults.

Abilify already is approved alone for the treatment of certain kinds of bipolar disorder in adults and adolescents. The psychiatric disorder causes unusual shifts in mood, energy and ability to function.

FDA also approved a new dosing regimen for adults taking the drug.

Otsuka Pharmaceutical and Bristol-Myers are collaborative partners in the development and marketing of Abilify in the United States and major European countries.

Shares of Bristol Myers Squibb Co. rose 21 cents Friday to $23 in after-hours trading, following an earlier close at $22.79.